Levazeo 25mg Tablet (Levosulpiride 25)

Description

Levazeo 25mg Tablet (Levosulpiride 25mg) — Complete Clinical and Patient Guide

Overview of Levazeo 25mg Tablet (Levosulpiride 25mg)

Levazeo 25mg Tablet (Levosulpiride 25mg) is a prescription pharmaceutical product containing Levosulpiride 25mg as its active ingredient. It belongs to the selective dopamine D2-receptor antagonist with 5-HT4 agonist activity (prokinetic) and is prescribed for functional dyspepsia, GERD-associated gastroparesis, nausea and vomiting, postprandial bloating and fullness, and irritable bowel syndrome with dyspeptic features. This comprehensive guide provides medically accurate, evidence-based information for patients and healthcare professionals, in accordance with YMYL (Your Money Your Life) content standards. All information presented here is derived from established pharmacological literature, regulatory prescribing information, and peer-reviewed clinical studies.

Gastrointestinal acid-related disorders — including gastroesophageal reflux disease (GERD), peptic ulcer disease, dyspepsia, and gastroparesis — affect hundreds of millions of individuals worldwide and significantly reduce quality of life. Proper pharmacological management is essential not only to relieve symptoms but also to prevent serious complications including oesophageal erosion, ulcer haemorrhage, and gastric malignancy. Levazeo 25mg addresses these conditions through a clinically validated pharmacological mechanism that has been refined over decades of research and clinical application.

Levazeo 25mg contains Levosulpiride, which acts on D2 and 5-HT4 receptors to restore normal coordinated gastrointestinal motility. The prokinetic mechanism addresses the motility dysfunction underlying many upper GI conditions that acid suppression alone cannot fully correct, making Levosulpiride-containing products particularly valuable in patients with gastroparesis, bloating, or postprandial fullness.

About the Active Ingredient: Levosulpiride 25mg

Levosulpiride 25mg belongs to the selective dopamine D2-receptor antagonist with 5-HT4 agonist activity (prokinetic). The drug has been extensively studied in randomised controlled trials and observational studies across diverse patient populations, establishing a well-characterised efficacy and safety profile. Its mechanism of action targets the fundamental pathophysiology of acid-related gastrointestinal disorders at the molecular level, providing reliable, measurable acid suppression or motility improvement that translates directly into clinical benefit for patients.

The pharmacokinetic profile of Levosulpiride 25mg is important for understanding its clinical use. Following oral administration, the drug undergoes absorption through the gastrointestinal mucosa and undergoes first-pass hepatic metabolism before reaching systemic circulation. The resulting pharmacologically active compound exerts its therapeutic effect at specific molecular targets in the gastrointestinal tract. Duration of action, onset of effect, and the degree of acid suppression or prokinetic activity are all clinically relevant parameters that influence dosing decisions and treatment outcomes.

Mechanism of Action

Levosulpiride is the levo-isomer of sulpiride, a selective D2 receptor antagonist with additional agonist activity at 5-HT4 serotonin receptors. Its prokinetic action results from dual mechanisms: D2 receptor blockade removes inhibitory dopaminergic control of GI smooth muscle, while 5-HT4 agonism directly stimulates acetylcholine release from enteric motor neurons, potentiating coordinated peristaltic activity. This dual action produces superior prokinetic efficacy compared to pure D2 antagonists. Levosulpiride accelerates gastric emptying, improves gastroduodenal coordination, enhances lower oesophageal sphincter tone, and relieves symptoms of functional dyspepsia, gastroparesis, and GERD-associated bloating and early satiety. At low doses (25–50mg), it exerts predominantly peripheral prokinetic activity; at higher doses (75mg SR), some central dopamine antagonism may contribute to antiemetic effects.

Understanding the mechanism of action is essential for appreciating why the drug must be taken at specific times relative to meals, why certain interactions occur with other medications, and why the full therapeutic effect may not be apparent immediately after initiation. Healthcare providers use knowledge of the mechanism to individualise dosing, anticipate interactions, and counsel patients on what to expect during treatment.

Clinical Indications

Levazeo 25mg Tablet (Levosulpiride 25mg) is indicated for the following conditions, either as monotherapy or as part of combination therapeutic regimens:

• Gastroesophageal Reflux Disease (GERD): Characterised by chronic reflux of gastric contents causing oesophageal mucosal injury and symptoms including heartburn and regurgitation. Pharmacological acid suppression or motility improvement is the cornerstone of GERD management.
• Peptic Ulcer Disease: Gastric and duodenal ulcers caused by Helicobacter pylori infection, NSAID use, or acid hypersecretion require sustained acid suppression for mucosal healing and ulcer prevention.
• Acid-Related Dyspepsia: Functional or organic dyspepsia with symptoms of upper abdominal pain, bloating, and nausea responds to acid suppression and/or prokinetic therapy.
• H. pylori Eradication: As a component of triple or quadruple antibiotic eradication regimens, acid suppression raises intragastric pH to enhance antibiotic bactericidal activity against H. pylori.
• Additional Indications Specific to Levazeo 25mg: functional dyspepsia, GERD-associated gastroparesis, nausea and vomiting, postprandial bloating and fullness, and irritable bowel syndrome with dyspeptic features.

Dosage and Administration

For functional dyspepsia: Levosulpiride 25–50mg two to three times daily before meals, or Levosulpiride SR 75mg once daily. Levazeo 25mg is the 25mg formulation — follow your prescriber’s dosing instructions carefully. Duration: typically 4–8 weeks for acute dyspepsia; reassess periodically for long-term use.

Adherence to the prescribed dosing schedule is critical for achieving therapeutic efficacy. Missing doses or irregular timing can significantly reduce acid suppression levels and delay symptom resolution or mucosal healing. Patients should be counselled on the importance of consistent, daily dosing for the prescribed duration, even if symptoms improve before the treatment course is complete.

Who Should Use Levazeo 25mg Tablet (Levosulpiride 25mg)

This medication is appropriate for adult patients diagnosed by a qualified healthcare professional with conditions listed in the indications section above. It is particularly beneficial for patients with documented endoscopic evidence of oesophagitis, confirmed peptic ulcer disease, or symptomatic GERD significantly impacting quality of life. Patients requiring concurrent NSAID therapy who have risk factors for GI complications (age over 65, history of ulcer disease, concurrent corticosteroid or anticoagulant use) also benefit from prophylactic acid suppression.

Contraindications — Who Should Not Use This Medication

Absolute contraindications: Known hypersensitivity to levosulpiride or sulpiride. Parkinson’s disease (dopamine antagonism worsens motor symptoms). Prolactinoma. Phaeochromocytoma. GI obstruction or haemorrhage. Epilepsy (may lower seizure threshold). Concurrent use of other dopamine agonists (L-DOPA, dopamine agonists for Parkinson’s). History of tardive dyskinesia. Use with caution in elderly patients due to increased EPS risk.

Prescribers must review the patient’s complete medication list and medical history before initiating therapy. Self-medication with prescription gastrointestinal agents is strongly discouraged, as undiagnosed upper GI symptoms may mask serious underlying conditions including gastric malignancy, which requires prompt diagnosis and appropriate treatment. Unexplained weight loss, dysphagia, haematemesis, melaena, or new onset symptoms in patients over 55 years should prompt urgent endoscopic evaluation before empirical acid suppression therapy is started.

Drug Interactions

Levosulpiride interactions: Anticholinergic agents — oppose levosulpiride’s prokinetic effect. Dopamine agonists (levodopa, pramipexole, ropinirole) — direct pharmacological antagonism reducing efficacy of both agents. Concurrent use with other dopamine antagonists increases EPS risk. CNS depressants — additive sedation. QTc-prolonging drugs — increased arrhythmia risk. Opioids — reduce prokinetic efficacy. Alcohol — increased CNS depression.

Before starting Levazeo 25mg Tablet (Levosulpiride 25mg), patients should inform their healthcare provider of all prescription medications, over-the-counter drugs, herbal supplements, and vitamins they are currently taking. Drug interaction checks should be performed by a qualified pharmacist or physician, as some interactions may be clinically significant and require dosage adjustments or alternative therapy selection.

Adverse Effects and Side Effects

Common adverse effects: Drowsiness, dizziness, dry mouth, and abdominal discomfort are commonly reported with levosulpiride, particularly at initiation.

Hormonal effects: Like all D2 antagonists that cross the blood-brain barrier even modestly, levosulpiride can elevate serum prolactin, causing galactorrhoea, amenorrhoea, gynaecomastia, and sexual dysfunction with prolonged use. These effects are generally dose-dependent and reversible upon drug discontinuation.

Extrapyramidal effects: Although less common than with metoclopramide, levosulpiride may cause extrapyramidal symptoms (EPS) including tremor, rigidity, akathisia, and tardive dyskinesia — particularly in elderly patients or with prolonged high-dose use. Regular neurological assessment is recommended for long-term users. Levosulpiride is contraindicated in patients with Parkinson’s disease.

Not all patients experience side effects, and many who do find them mild and transient. However, patients should be educated about the signs of serious adverse effects requiring prompt medical attention — in particular, severe allergic reactions (anaphylaxis), severe skin reactions, signs of C. difficile infection (severe or persistent diarrhoea), and symptoms of hypomagnesaemia (muscle cramps, irregular heartbeat, seizures).

Special Population Considerations

Neurological monitoring: Regular assessment for extrapyramidal symptoms (EPS) — particularly tremor, rigidity, and tardive dyskinesia — is recommended in patients on long-term levosulpiride, especially elderly individuals.

Hormonal effects: Prolactin levels may be elevated with long-term use. Patients experiencing galactorrhoea, amenorrhoea, or breast pain should have serum prolactin measured.

Elderly: Increased EPS risk warrants reduced doses and vigilant neurological monitoring in older patients.

Renal impairment: Levosulpiride is primarily renally excreted; dose reduction is required in significant renal impairment.

Pregnancy and breastfeeding: Not recommended due to potential hormonal effects and limited safety data.

Monitoring during therapy: For patients on long-term therapy (more than 1 year), periodic monitoring of serum magnesium, vitamin B12 levels, renal function, and bone density (in high-risk patients) is recommended. Liver function tests should be assessed in patients with pre-existing hepatic conditions. Endoscopic reassessment may be required in patients with complicated GERD or those not responding to therapy.

Storage and Handling Instructions

Store Levazeo 25mg Tablet (Levosulpiride 25mg) at room temperature between 15°C and 25°C, in a dry location away from direct sunlight, heat sources, and moisture. Bathrooms and kitchen sinks are not suitable storage locations due to humidity exposure. Keep in the original manufacturer’s packaging until the dose is required. Store securely out of reach of children and pets. Never use medication beyond the printed expiry date. Dispose of unused or expired medication through authorised pharmaceutical take-back programmes — do not flush down the drain or discard in household waste.

Frequently Asked Questions

Q: How should I store this medication?
A: Store at room temperature (15–25°C), away from direct sunlight, heat, and moisture. Keep in original packaging and out of reach of children. Do not use after the expiry date.

Q: What should I do if I miss a dose?
A: Take the missed dose as soon as you remember, unless it is nearly time for your next scheduled dose. Never double-dose to make up for a missed one. If unsure, consult your pharmacist or doctor.

Q: Can I stop taking this medication once my symptoms improve?
A: Do not stop the medication without consulting your doctor. Many acid-related conditions require a full course of treatment even after symptoms resolve to ensure complete mucosal healing and prevent relapse.

Q: Is it safe to take this medication long-term?
A: Long-term use may be appropriate for certain conditions under medical supervision, but requires the lowest effective dose and periodic reassessment by a healthcare provider. Long-term PPI use warrants monitoring for hypomagnesaemia, vitamin B12 levels, and bone health.

Q: Can I take Levosulpiride long-term?
A: Long-term use requires regular neurological assessment for extrapyramidal symptoms and monitoring for hyperprolactinaemia. The dose should be periodically reviewed and reduced to the minimum effective level. Discuss duration of therapy with your gastroenterologist.

Important Medical Disclaimer

The information on this product page is provided for general educational purposes and is intended to support — not replace — the professional judgement of qualified healthcare providers. This content has been prepared in accordance with YMYL (Your Money Your Life) standards to ensure accuracy, balance, and patient safety. All drug therapy decisions must be made by a licensed physician or pharmacist with full knowledge of the patient’s medical history, comorbidities, and concurrent medications. Self-diagnosis and self-treatment of gastrointestinal conditions using prescription medications without medical supervision can be dangerous and may result in delayed diagnosis of serious underlying conditions. If you have questions about this medication or your treatment, please consult your doctor or pharmacist.